X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs VENUS REMEDIES - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS VENUS REMEDIES NOVARTIS/
VENUS REMEDIES
 
P/E (TTM) x 363.2 -681.0 - View Chart
P/BV x 17.9 0.2 8,977.3% View Chart
Dividend Yield % 1.6 0.0 -  

Financials

 NOVARTIS   VENUS REMEDIES
EQUITY SHARE DATA
    NOVARTIS
Mar-16
VENUS REMEDIES
Mar-16
NOVARTIS/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs982218 450.5%   
Low Rs55682 677.5%   
Sales per share (Unadj.) Rs252.9365.6 69.2%  
Earnings per share (Unadj.) Rs62.11.5 4,181.9%  
Cash flow per share (Unadj.) Rs63.337.9 166.9%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs363.6382.5 95.1%  
Shares outstanding (eoy) m31.9611.44 279.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.00.4 741.0%   
Avg P/E ratio x12.4101.0 12.3%  
P/CF ratio (eoy) x12.24.0 307.1%  
Price / Book Value ratio x2.10.4 539.2%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m24,5801,717 1,431.9%   
No. of employees `0000.81.0 73.7%   
Total wages/salary Rs m1,801324 555.2%   
Avg. sales/employee Rs Th10,748.94,100.7 262.1%   
Avg. wages/employee Rs Th2,395.2318.0 753.1%   
Avg. net profit/employee Rs Th2,641.116.7 15,846.5%   
INCOME DATA
Net Sales Rs m8,0834,183 193.3%  
Other income Rs m82920 4,126.4%   
Total revenues Rs m8,9134,203 212.1%   
Gross profit Rs m234812 28.9%  
Depreciation Rs m37417 8.8%   
Interest Rs m2380 0.5%   
Profit before tax Rs m1,02535 2,920.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m75218 4,154.7%   
Profit after tax Rs m1,98617 11,682.9%  
Gross profit margin %2.919.4 14.9%  
Effective tax rate %73.451.6 142.3%   
Net profit margin %24.60.4 6,045.4%  
BALANCE SHEET DATA
Current assets Rs m12,6782,771 457.6%   
Current liabilities Rs m2,4331,931 126.0%   
Net working cap to sales %126.720.1 631.6%  
Current ratio x5.21.4 363.2%  
Inventory Days Days33125 26.1%  
Debtors Days Days2254 41.8%  
Net fixed assets Rs m695,328 1.3%   
Share capital Rs m160114 139.7%   
"Free" reserves Rs m11,4604,177 274.4%   
Net worth Rs m11,6214,376 265.6%   
Long term debt Rs m01,911 0.0%   
Total assets Rs m14,4008,428 170.8%  
Interest coverage x570.51.1 52,223.6%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.5 113.1%   
Return on assets %13.84.7 293.2%  
Return on equity %17.10.4 4,399.5%  
Return on capital %23.66.6 357.2%  
Exports to sales %0.70-   
Imports to sales %18.620.5 90.6%   
Exports (fob) Rs m60NA-   
Imports (cif) Rs m1,503858 175.1%   
Fx inflow Rs m1860-   
Fx outflow Rs m1,821858 212.1%   
Net fx Rs m-1,635-858 190.4%   
CASH FLOW
From Operations Rs m2,531469 539.9%  
From Investments Rs m-8,27029 -28,320.9%  
From Financial Activity Rs m-386-464 83.2%  
Net Cashflow Rs m-6,12535 -17,752.2%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.2 1,111.1%  
FIIs % 1.6 0.6 275.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 66.4 32.4%  
Shareholders   41,647 20,121 207.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   WYETH LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue to Fall, IT Sector Growth Projections, and Top Stocks in Action(Pre-Open)

On Wednesday, share markets in India opened in green but ended on a weak note. The BSE Sensex closed lower by 71 points to end the day at 33,704.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 20, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS